DarioHealth (Nasdaq:DRIO) today announced real-world study data on the impact of managing diabetes and weight on a single digital platform.
New York-based DarioHealth presented the published retrospective, real-world study observing its digital therapeutics platform at the Advanced Technologies and Treatments for Diabetes (ATTD) Conference in Barcelona.
The company analyzed 12 months of data for a group of 715 individuals using the Dario app to manage their blood sugar aat a body mass index (BMI) of greater than 30 kg/m2, the clinical baseline for obesity. According to a news release, nearly two-thirds of DarioHealth participants in the study with a BMI of more than 30 reduced their BMI by an average of 2.8 units with an average weight loss of 7.4%.
A subgroup of Dario participants with BMIs greater than 30 and high-risk blood glucose readings of more than 180 mg/dL was observed as well to understand the impact on both diabetes and weight management. The subgroup also saw improved clinical outcomes, with weight reduction averaging 4.9% and average blood glucose reduction averaging 16.1% over 12 months.
“I am proud to share new evidence that Dario’s approach to providing user-centric support for common, co-occurring chronic conditions can make a significant difference for the people we help,” DarioHealth Scientific and Clinical Director and study supervisor Yifat Hershcovitz said in the release. “This research, combined with our previous study showing improvements in overall health for people living with diabetes and high blood pressure, offer a compelling argument for digital solutions that prioritize a whole health experience.”